Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!

Unlocking the Future of Hematology: A Sneak Peek into ASH 2023 Discoveries!

Dec 08, 2023

The upcoming 65th American Society of Hematology (ASH) Annual Meeting and Exposition 2023 is just around the corner, and leading pharmaceutical giants like BMS, Genmab, AstraZeneca, Regeneron, BeiGene, ADC Therapeutics, Eli Lilly and Company, Janssen, and others are gearing up for this conference. This conference will provide a platform to highlight the expanding array of treatment options available for blood cancers and disorders. The focus lies on identifying key abstracts that are anticipated to leave a lasting impression, sparking significant interest throughout the event.

Highlighting the Featured Abstracts at ASH 2023: A Must-See List!

Company	Drug	Trial ID/ Acronym	Phase	Abstract No.	Abstract Title
Diffuse large B cell lymphoma (DLBCL)
$C:\Users\HP00\Desktop\Comapny's Logo\download (36).png$	Odronextamab	NCT03888105 (ELM-2)	II	436	Final Analysis of the Phase 2 ELM-2 Study: Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
$C:\Users\HP00\Desktop\Comapny's Logo\JOBS-LOGO-en-us-1600113636581.png$	Lisocabtagene maraleucel	NCT03483103(PILOT)	II	105	Lisocabtagene Maraleucel as Second-Line Therapy for R/R Large B-Cell Lymphoma in Patients Not Intended for Hematopoietic Stem Cell Transplant: Final Analysis of the Phase 2 PILOT Study
$C:\Users\HP00\AppData\Local\Microsoft\Windows\INetCache\Content.MSO\3EB82D25.tmp$	Epcoritamab + lenalidomide	NCT05283720 (EPCORE NHL-5)	II	438	Subcutaneous Epcoritamab Plus Lenalidomide in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma from EPCORE NHL-5
$C:\Users\HP00\AppData\Local\Microsoft\Windows\INetCache\Content.MSO\6D8E9DBF.tmp$	Bgb-16673	NCT05006716	I/II	4401	First Results from a Phase 1, First-in-Human Study of the Bruton’s Tyrosine Kinase Degrader Bgb-16673 in Patients with Relapsed or Refractory B-Cell Malignancies (BGB-16673-101)
$C:\Users\HP00\AppData\Local\Microsoft\Windows\INetCache\Content.MSO\3EB82D25.tmp$	Epcoritamab + GemOx	NCT04663347 (EPCORE NHL-2)	Ib/II	3092	Epcoritamab SC + GemOx Leads to High Complete Metabolic Response Rates in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Ineligible for Autologous Stem Cell Transplant: Updated Results from EPCORE NHL-2
	Epcoritamab + R-mini-CHOP	NCT04663347 (EPCORE NHL-2)	Ib/II	4457	Subcutaneous Epcoritamab + R-mini-CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Ineligible for Full-Dose Anthracycline: Results from the EPCORE NHL-2 Phase 1/2 Trial.
Follicular Lymphoma (FL)
$C:\Users\HP00\AppData\Local\Microsoft\Windows\INetCache\Content.MSO\3EB82D25.tmp$	Epcoritamab + rituximab + lenalidomide	NCT05409066 (EPCORE FL-1)	III	3053	EPCORE FL-1: Phase 3 Trial of Subcutaneous Epcoritamab With Rituximab and Lenalidomide (R2) vs R2 Alone in Patients With Relapsed or Refractory Follicular Lymphoma.
$C:\Users\HP00\Desktop\Comapny's Logo\download (32).png$	Loncastuximab tesirine + rituximab	NCT04998669	II	984	Limited Duration Loncastuximab Tesirine with Rituximab Induces High Complete Metabolic Response Rate in High-Risk Relapsed/Refractory Follicular Lymphoma – A Phase 2 Study
$C:\Users\HP00\AppData\Local\Microsoft\Windows\INetCache\Content.MSO\3EB82D25.tmp$	Epcoritamab	NCT03625037 (EPCORE NHL-1)	I/II	1655	Epcoritamab SC Monotherapy Drives Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: Results from the EPCORE NHL-1 Dose Expansion Cohort.
$C:\Users\HP00\Desktop\Comapny's Logo\download (1).png$	Pirtobrutinib	NCT03740529 (BRUIN)	I/II	3026	Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed/Refractory Follicular Lymphoma: Results from the Phase 1/2 BRUIN Study
Multiple Myeloma (MM)
$C:\Users\HP00\AppData\Local\Microsoft\Windows\INetCache\Content.MSO\CB007F7B.tmp$	Daratumumab (DARA) + bortezomib, lenalidomide, and dexamethasone	NCT03710603 (PERSEUS)	III	LBA1	Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Vrd Alone in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Eligible for Autologous Stem Cell Transplantation (ASCT): Primary Results of the Perseus Trial
$C:\Users\HP00\AppData\Local\Microsoft\Windows\INetCache\Content.MSO\CB007F7B.tmp$	Ciltacabtagene autoleucel	NCT04181827 (CARTITUDE-4)	III	1063	Patient-reported outcomes in the Phase 3 CARTITUDE-4 study of ciltacabtagene autoleucel versus standard of care in patients with lenalidomide-refractory multiple myeloma after 1-3 lines of therapy
$C:\Users\HP00\AppData\Local\Microsoft\Windows\INetCache\Content.MSO\CB007F7B.tmp$	Daratumumab, bortezomib, melphalan, and prednisone	NCT03217812 (OCTANS)	III	3388	Daratumumab, bortezomib, melphalan, and prednisone (D-VMP) versus bortezomib, melphalan, and prednisone (V-MP) alone in transplant-ineligible Asian patients with NDMM: final analysis of the Phase 3 OCTANS study
$C:\Users\HP00\AppData\Local\Microsoft\Windows\INetCache\Content.MSO\CB007F7B.tmp$	Daratumumab	NCT02316106(CENTAURUS)	II	210	Efficacy and safety of daratumumab monotherapy in patients with intermediate-risk or high-risk SMM: final analysis of the Phase 2 CENTAURUS study
$C:\Users\HP00\AppData\Local\Microsoft\Windows\INetCache\Content.MSO\6D8E9DBF.tmp$	Sonrotoclax (BGB-11417) + dexamethasone	NCT04973605	Ib/II	1011	Sonrotoclax (BGB-11417) in Combination with Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma with t(11;14): Safety, Efficacy, and Determination of Recommended Phase 2 Dose
$C:\Users\HP00\AppData\Local\Microsoft\Windows\INetCache\Content.MSO\3EB82D25.tmp$	GEN3014	NCT04824794	I/II	4757	GEN3014 (HexaBody-CD38) in Anti-CD38 mAb–Naive Patients with Relapsed/Refractory Multiple Myeloma: Preliminary Results from a Dose-Expansion Cohort of a Phase 1/2 Trial.
$C:\Users\HP00\AppData\Local\Microsoft\Windows\INetCache\Content.MSO\CB007F7B.tmp$	Talquetamab + pomalidomide	NCT05050097 (MonumenTAL-2)	Ib	1014	Talquetamab + pomalidomide in patients with RRMM: safety and preliminary efficacy results from the Phase 1b MonumenTAL-2 study
$C:\Users\HP00\AppData\Local\Microsoft\Windows\INetCache\Content.MSO\CB007F7B.tmp$	JNJ-79635322	NCT05652335	I	456	Characterization of JNJ-79635322, a novel BCMA x GPRC5D x CD3 T-cell redirecting trispecific antibody, for the treatment of multiple myeloma
$C:\Users\HP00\Desktop\Comapny's Logo\JOBS-LOGO-en-us-1600113636581.png$	BMS-986393	NCT04674813	I	219	BMS-986393 (CC-95266), a G protein–Coupled Receptor Class C Group 5 Member D (GPRC5D)–Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 Study
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
$C:\Users\HP00\AppData\Local\Microsoft\Windows\INetCache\Content.MSO\6D8E9DBF.tmp$	Sonrotoclax + zanubrutinib	NCT04277637	Ia/Ib	327	Combination Treatment with Sonrotoclax (BGB-11417), a Second-Generation BCL2 Inhibitor, and Zanubrutinib, a Bruton Tyrosine Kinase (BTK) Inhibitor, Is Well Tolerated and Achieves Deep Responses in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Data from an Ongoing Phase 1/2 Study
$C:\Users\HP00\AppData\Local\Microsoft\Windows\INetCache\Content.MSO\2125C241.tmp$	Lisaftoclax	NCT03913949, NCT04494503	Ib/II	1900	Updated Efficacy and Safety Results of Lisaftoclax (APG-2575) in Patients (pts) with Heavily Pretreated Chronic Lymphocytic Leukemia (CLL): Pool Analysis of Two Clinical Trials
Myelofibrosis
$C:\Users\HP00\AppData\Local\Microsoft\Windows\INetCache\Content.MSO\C90DFEF7.tmp$	Selinexor	NCT04562389 (XPORT-MF-034)	III	3209	A Global, Phase 3, Randomized, Double-Blind Study to Evaluate Safety and Efficacy of Selinexor, an XPO-1 Inhibitor in Combination with ruxolitinib in JAK Inhibitor-Naïve Myelofibrosis (XPORT-MF-034)
$C:\Users\HP00\AppData\Local\Microsoft\Windows\INetCache\Content.MSO\B8FF7B1D.tmp$	Pelabresib + ruxolitinib	NCT04603495	III	628	Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Patients with Myelofibrosis: Results of the MANIFEST-2 Randomized, Double-Blind, Phase 3 Study
Mantle cell lymphoma (MCL)
$C:\Users\HP00\AppData\Local\Microsoft\Windows\INetCache\Content.MSO\7A581833.tmp$	Ibrutinib + venetoclax	NCT03112174 (SYMPATICO)	III	LBA2	Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis Results from the Randomized Phase 3 Sympatico Study
	Acalabrutinib + venetoclax and rituximab	NCT05951959 (TrAVeRse)	II	3054	TrAVeRse: A Phase 2, Open-Label, Randomized Study of Acalabrutinib in Combination with Venetoclax and Rituximab in Patients with Treatment- naïve Mantle Cell Lymphoma
$C:\Users\HP00\Desktop\Comapny's Logo\download (1).png$	Pirtobrutinib	NCT03740529(BRUIN)	I/II	981	Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) Patients with Prior cBTKi: Safety and Efficacy Including High-Risk Subgroup Analyses from the Phase 1/2 BRUIN Study